CPX-351
CLTR0310-206
Phase 2 small_molecule completed
Quick answer
CPX-351 for Acute Myeloid Leukemia (AML) is a Phase 2 program (small_molecule) at Jazz Pharmaceuticals plc with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Jazz Pharmaceuticals plc
- Indication
- Acute Myeloid Leukemia (AML)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed